Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab

Autor: C. Mallinckrodt, Y. Tian, P.S. Aisen, F. Barkhof, S. Cohen, G. Dent, O. Hansson, K. Harrison, T. Iwatsubo, C.J. Mummery, K.K. Muralidharan, I. Nestorov, L. Nisenbaum, R. Rajagovindan, C. von Hehn, C.H. van Dyck, B. Vellas, S. Wu, Y. Zhu, A. Sandrock, T. Chen, S. Budd Haeberlein

Publikováno v: Mallinckrodt, C, Tian, Y, Aisen, P S, Barkhof, F, Cohen, S, Dent, G, Hansson, O, Harrison, K, Iwatsubo, T, Mummery, C J, Muralidharan, K K, Nestorov, I, Nisenbaum, L, Rajagovindan, R, von Hehn, C, van Dyck, C H, Vellas, B, Wu, S, Zhu, Y, Sandrock, A, Chen, T & Budd Haeberlein, S 2023, ' Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab ', Journal of Prevention of Alzheimer's Disease, vol. 10, no. 2, pp. 171-177 . https://doi.org/10.14283/jpad.2023.6
Journal of Prevention of Alzheimer's Disease, 10(2), 171-177. Springer International Publishing AG

Objectives: Efficacy and safety results from the EMERGE (NCT02484547) and ENGAGE (NCT02477800) phase 3 studies of aducanumab in early Alzheimer’s disease (AD) have been published. In EMERGE, but not in ENGAGE, high-dose aducanumab demonstrated sign

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd07dbe73e27c792379e4f551475c168
https://research.vumc.nl/en/publications/18353bb7-a328-4866-843c-42c58403e679

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease

Autor: S. Budd Haeberlein, P.S. Aisen, F. Barkhof, S. Chalkias, T. Chen, S. Cohen, G. Dent, O. Hansson, K. Harrison, C. von Hehn, T. Iwatsubo, C. Mallinckrodt, C.J. Mummery, K.K. Muralidharan, I. Nestorov, L. Nisenbaum, R. Rajagovindan, L. Skordos, Y. Tian, C.H. van Dyck, B. Vellas, S. Wu, Y. Zhu, A. Sandrock

Publikováno v: Journal of Prevention of Alzheimer's Disease, 9(2), 197-210. Springer International Publishing AG
Budd Haeberlein, S, Aisen, P S, Barkhof, F, Chalkias, S, Chen, T, Cohen, S, Dent, G, Hansson, O, Harrison, K, von Hehn, C, Iwatsubo, T, Mallinckrodt, C, Mummery, C J, Muralidharan, K K, Nestorov, I, Nisenbaum, L, Rajagovindan, R, Skordos, L, Tian, Y, van Dyck, C H, Vellas, B, Wu, S, Zhu, Y & Sandrock, A 2022, ' Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease ', Journal of Prevention of Alzheimer's Disease, vol. 9, no. 2, pp. 197-210 . https://doi.org/10.14283/jpad.2022.30

Background: Alzheimer’s disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is a human monoclonal antibody directed against aggregated soluble an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25356f937683da76b27d9eec33c332a0
https://research.vumc.nl/en/publications/104cb695-ffcb-4502-aba8-9ab998dcbd40

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.